Tag Archives: healthcare

Verdane and Bpifrance partner with Medadom to expand access to healthcare services in France and across Europe

Verdane Capital

Verdane, the European specialist growth buyout investment firm, today announces an investment into and partnership with Medadom, a leading French teleconsultation provider, alongside Bpifrance, the French sovereign fund.

Verdane has extensive experience navigating regulated reimbursement environments and scaling technology-enabled healthcare platforms such as Pflegecampus, Evondos and Smartbox.

Founded in 2017, Medadom has played a pioneering role in shaping teleconsultation in France. The company was the first teleconsultation provider to receive accreditation from the French Ministry of Health and has established a leading position in the market through a high-quality, secure and accessible model of care.

In addition to its pure digital offering, Medadom operates 5,500 physical teleconsultation units in pharmacies and optical stores across France and has facilitated more than 9 million teleconsultations. The company provides an important digital healthcare solution in areas affected by limited access to medical professionals, helping to improve access to care for underserved populations.

The investment will support Medadom in expanding access to healthcare services in France and across Europe, broadening its service to include additional care verticals and further strengthening its medical governance and technology platform. Over time, the partnership is also intended to support a measured expansion into other European markets, building on the company’s established position in France.

As part of the transaction, Medadom founders Elie-Dan Mimouni and Nathaniel Bern regain majority ownership of the business as they partner with Verdane and Bpifrance to support the next stage of the company’s development. Medadom’s former partner Gsquare Capital has realised its investment in the business.

The investment in Medadom marks Verdane’s first investment in France, a natural step for the firm as it continues its European growth investment strategy.

Completion of the transaction is expected later in 2026, subject to customary regulatory approvals and closing conditions.

Elie-Dan Mimouni, Co-Founder of Medadom, said: “Verdane and Bpifrance’s investments mark a strategic milestone for Medadom. Their combined expertise in healthcare and technology will enable us to create even greater value for patients, our partner pharmacists and opticians, as well as for the physicians practicing on our platform, while further consolidating a demanding, responsible model centered on the quality of medical care delivery.”

Moez Gharbi, Partner at Verdane, said: “Our in-depth analysis of the healthcare technology sector made it clear that Medadom stands out as a trusted, scalable leader in telehealth. Its distinctive model combines medical excellence with accessible, technology-enabled care. We have been particularly impressed by the powerful flywheel inherent to its unique digital and phygital approach, the strength of its governance and its clear commitment to responsible healthcare delivery. At the same time, it is encouraging to see French authorities taking thoughtful steps to improve access to care, particularly in underserved areas. We look forward to working closely with Elie-Dan, Nathaniel and the wider Medadom team along with Bpifrance to invest in the company’s continued growth.”

Benoist de Saint Lager, Senior Investment Director at Bpifrance said: “Our investment in Medadom is fully aligned with our investment thesis: addressing the major societal challenge of providing healthcare access for everyone across the country. Teleconsultations have proven to be an effective way to tackle healthcare accessibility issues, ease pressure on the healthcare system by increasing available medical time and relieve congestion in hospital emergency departments. As Medadom’s partner, Bpifrance aims to support the long-term development of its teleconsultation offer in France, where there is still significant room for market penetration improvement when compared with some European neighbours that are currently more advanced in the telehealth field.”

About Medadom

Founded in 2017, Medadom is a French teleconsultation provider accredited by the French Ministry of Health. The company delivers secure and patient-centred remote medical consultations through a network of more than 5,500 teleconsultation kiosks located in pharmacies and optical stores across France. With more than 9 million consultations completed, Medadom plays a central role in improving access to healthcare, particularly in medically underserved areas. The company has been part of the French Tech 120 programme since 2021, a Government-led flagship initiative designed to support and accelerate the growth of France’s most promising scale-ups.

About Verdane

Verdane is a specialist growth buyout investment firm that partners with tech-enabled and sustainable businesses that help to digitalise and decarbonise the European economy. The flexible mandates of Verdane funds allow it to invest as a majority or minority control investor, replacement or growth capital, in single companies or in portfolios of companies

Verdane has raised €9 billion in capital and its funds have made more than 200 investments in fast-growing businesses since 2003. Verdane’s team of over 150 investment professionals and operating experts is based out of Berlin, Copenhagen, London, Helsinki, Munich, Oslo and Stockholm and combines deep sector expertise with long-standing local networks and presence in core European markets.

Verdane is also a certified B Corporation, the most ambitious sustainability accreditation globally. The firm only backs businesses that pass its 2040 test, which indicates whether the company can thrive in a more sustainable future economy.

Verdane is partly owned by the Verdane Foundation, which is focused on two areas: climate change and more equitable and inclusive local communities.

More info: www.verdane.com
Follow Verdane on LinkedIn

Press Contact

Verdane Press Office
press@verdane.com

About Bpifrance

Bpifrance Investissement is the management company that handles Bpifrance’s equity investments. Bpifrance is the French national investment bank: it finances businesses – at every stage of their development – through loans, guarantees, equity investments and export insurances. Bpifrance also provides extra financial services (training, consultancy) to help entrepreneurs meet their challenges (innovation, export…). For more information, please visit: https://www.bpifrance.com/ Follow us on Twitter: @Bpifrance – @BpifrancePresse and LinkedIn.

Categories: News

Tags:

819 Capital Partners acquires key assets of Lead Pharma, enabling continuation of operations

819 Capital Partners

Deventer, 6 March 2026 – 819 Capital Partners has acquired the key assets of Lead Pharma, thereby realizing a continuation based on the company’s patent portfolio and associated research programs.

The transaction includes intellectual property rights, research data, and selected development programs.

Lead Pharma develops innovative small-molecule medicines for the treatment of cancer and autoimmune diseases. Over the past years, the company built a strong research platform and multiple drug candidates, collaborating with international pharmaceutical companies such as Roche and Sanofi.

The acquisition is realized by 819 Capital Partners, through its 819 Evergreen Fund, together with Waterman Ventures and the former management of Lead Pharma. Going forward, the focus will be on the further development and valorization of the most promising components of the portfolio of Lead Pharma.

Following a period of financial restructuring, the activities have been secured through an asset transaction. This transaction lays a new foundation for the continuation and further development of the programs, and for entering into new collaborations aimed at advancing development.

Frans van den Berg, Chief Executive Officer of Lead Pharma, commented: “This asset acquisition with the support of 819 Capital Partners enables us to continue Lead Pharma’s projects in a focused manner and to make the development of new medicines for patients possible.”

819 Capital Partners views the transaction as a strategic investment in a mature biotech patent portfolio, with the aim of advancing the development of the programs and creating value through further development and strategic partnerships.

About 819 Capital Partners

819 Capital Partners is an investment firm managing multiple funds with targeted investment strategies. Its open-ended 819 Evergreen Fund is quarterly open for new investors and invests in companies focused on deep-tech and med-tech. The firm invests in sectors such as healthcare and technology, addressing societal challenges including aging populations.

Categories: News

Tags:

Axon Diagnostics joins Medica Group to enhance UK diagnostic services

IK Partners

On 13 February Axon Diagnostics joined Medica Group, marking an exciting new chapter for our organisation and for the future of remote diagnostics in the UK.

By joining forces, we will become the UK’s largest clinical reporting network, supporting more than 2.5 million patients each year across the majority of NHS Trusts. This step reflects our shared ambition to accelerate innovation and gives us the scale, and capability, to support even more patients with faster, accurate reporting.

As part of this integration, Axon’s sister company, MITIS Health, will also join Medica. MITIS brings its Clinical Desktop technology, already trusted by many NHS Trusts, to support high fidelity remote diagnostic reporting.

Strengthening our capabilities together

For more than 20 years, we have built a robust network of specialist clinicians, supported by strong clinical governance and advanced infrastructure. By welcoming Axon and MITIS into the Medica Group, we are enhancing this foundation even further.

Axon is known for its innovative technology platform, agile workflows, and secure, high-performance remote desktop solutions powered by MITIS Clinical Desktop. These tools allow clinicians to work with complete flexibility, seamlessly and securely, from any appropriate location. Axon also brings a team of highly skilled clinicians who have earned a reputation for their quality and responsiveness.

Together, these strengths mean we can offer:

  • More capacity for clients across the UK
  • Faster turnaround times for routine and urgent cases
  • An enhanced experience for both healthcare partners and patients
  • A stronger platform for innovation, including AI-enabled reporting and optimised workflows

The UK’s largest clinical reporting network

With Axon joining Medica, we will be working with the majority of NHS Trusts and covering a broad range of diagnostic subspecialties.

Both organisations share the same commitment: to act as trusted strategic partners and deliver consistent, transparent, high-quality diagnostic services. Our clients will continue to work with the same familiar teams, while gradually benefiting from enhanced tools, streamlined workflows, and increased flexibility as our systems integrate.

Leadership insights

Andrew Cannon, Chief Executive Officer of Medica Group, said: “This merger marks a significant milestone for Medica, and we are proud to welcome Axon into the Medica Group. The Axon team has built an exceptional business in a remarkably short time, earning the trust of clients through first-rate service, agility and a deep commitment to quality. Bringing Axon into Medica strengthens our position as the UK’s leading diagnostics provider. Clients will continue to receive the excellent service they rely on, now supported by greater capacity and advanced reporting technology. We look forward to building a compelling future together, driving further innovation and delivering outstanding patient care at the core of our mission.”

Rahul Mehta, Chief Executive Officer of Axon Diagnostics, said: “Axon was founded to push the boundaries of diagnostic innovation, and joining Medica enables us to amplify that mission. This merger combines our technology and agile approach with Medica’s scale and clinical excellence, meaning more patients will benefit from faster and smarter reporting. We’re excited to enter this next chapter together, bringing our teams and clients with us into the Medica Group as we continue building trusted, high-quality diagnostic services.”

What happens next

We are now working through a phased integration plan that will bring together our systems, teams, and best practices in a structured and transparent way. While this integration progresses, our focus remains firmly on delivering reliable, high-quality diagnostic services that place patients at the centre of every decision we make. We look forward to the opportunities this partnership will unlock as we continue working together to deliver the highest standards of diagnostic care.

Contacts

Medica
Helen Lawton
Group Head of Marketing, Communications and Events
Email: Helen.lawton@medica.co.uk
Tel: 07950179069

FTI Consulting
Ben Atwell / Sam Purewal
Email : medica@fticonsulting.com
Tel: +44 (0) 203 727 1000

About Medica

Medica Group is the UK’s largest telemedicine diagnostics provider, delivering expert teleradiology and telepathology services to over half of NHS hospitals nationwide. With more than 20 years’ experience in remote diagnostics, Medica provides 24/7 coverage for urgent and routine imaging via a network of 800+ specialist clinicians across the UK, Ireland and the US. Its innovative platforms and use of AI-enhanced workflows help healthcare providers reduce imaging backlogs and improve patient outcomes. Headquartered in Hastings, UK, Medica Group also encompasses Medica Ireland (managed radiology and pathology services in Ireland) and RadMD in the USA (clinical trial imaging), underscoring its international reach and commitment to “improving lives through excellence in diagnostics and research.”

Read More 

About Axon Diagnostics

Axon Diagnostics is a UK-based, clinically led diagnostics services provider delivering radiology, teleradiology and digital pathology services to the NHS and private healthcare organisations. Axon offers a suite of solutions to support the needs of modern diagnostic imaging services, underpinned by innovative, secure streaming technology that enables efficient reporting, supports clinicians, and delivers tangible benefits for patient care. Axon Diagnostics – Radiology Reimagined.

Read More 

About MITIS Health

MITIS Health is a UK-based technology provider focused on improving diagnostic workflows. MITIS Health has built the Next Generation Home and inHospital Reporting Solution for Radiology, Pathology and Clinical Desktops. The Company’s Secure Gateway allows clinicians working remotely to securely project a desktop located in the hospital or datacentre, directly to any appropriate remote location. Complete lossless transmission / zero degradation of images is supported for all light-based scans such as: Plain Film, CT, MRI, PET, Ultrasound and Histopathology.

Read More 

Categories: News

Tags:

EQT Foundation announces Rare Disease Science Grant recipients

eqt

EQT Foundation is proud to announce the recipients of its Rare Disease Science Grants, a funding initiative designed to accelerate transformative deeptech solutions for the diagnosis, treatment, and management of rare conditions. The selected projects span gene and RNA therapies, regenerative medicine, AI-enabled diagnostics, novel drug delivery platforms, and precision immunotherapy, each addressing urgent unmet needs in diseases that disproportionately affect children and underserved patient populations.

Together, these projects exemplify the power of rare disease research to generate breakthroughs with impact far beyond individual conditions, advancing new platforms, tools, and approaches that can reshape medicine more broadly.

Meet the Grantees

Spencer Shelton – Modulating metabolic flux by hematopoietic stem cell engineering to ameliorate porphyrias

A broadly applicable genetic therapy for erythropoietic protoporphyria that targets blood stem cells to restore balance in heme biosynthesis. By intervening at a shared regulatory point rather than correcting individual mutations, this approach aims to deliver a mutation-agnostic therapy capable of reaching clinical testing by the end of the project.

Daniel Bauer – Prime editing gene therapy for Shwachman-Diamond syndrome

This project advances a first-in-class prime editing strategy to treat Shwachman-Diamond syndrome, a rare inherited bone marrow failure disorder with no targeted therapies. Building on strong proof-of-concept data, the team will generate the preclinical and genotoxicity evidence needed to support a pre-IND meeting with the FDA, with the longer-term goal of establishing a gene-editing platform for blood and immune diseases.

Rhian Stavely – Autologous enteric neural stem cells for Hirschsprung disease

A curative regenerative medicine approach for children with Hirschsprung disease, which is caused by the absence of enteric neurons in the gut. Using a patient’s own cells, this project aims to regenerate functional enteric neural networks, restore gut motility, and reduce lifelong complications, while preparing the therapy for first-in-human clinical translation.

Marta M. Alonso and Iker Ausejo-Mauleón –Developing new generation oncolytic virus for pediatric brain tumors

This project is developing next-generation oncolytic virus therapies for otherwise incurable pediatric brain tumors, with a focus on diffuse midline gliomas. The grant will support advanced preclinical validation of POP-02, alongside regulatory planning toward first-in-human studies in Europe and the United States, with the ambition to initiate a Phase I trial in children.

Guei-Sheung Liu – Transformative RNA editing therapy for Usher syndrome

This project from the Centre for Eye Research Australia, is developing a first-in-class RNA editing therapy to directly correct the genetic cause of Usher syndrome, a condition that leads to irreversible vision loss and early-onset hearing impairment. By restoring essential retinal proteins, the approach has the potential to halt retinal degeneration and transform outcomes for up to 300,000 people worldwide.

Timothy Jenkins – AI-designed T-cell engagers for virus-driven Merkel cell carcinoma

Using de novo protein design, this project creates highly selective bispecific T-cell engagers that target viral peptide–MHC complexes in Merkel cell carcinoma, a rare and aggressive skin cancer. The platform combines generative AI with in vitro and in vivo validation to deliver a preclinical lead with a clear path toward IND-enabling studies and broader applicability to other virus-associated cancers.

Wouter van Rheenen and Vamshidhar R. Vangoor – ATTAIN: Antisense therapies targeting ALS in induced neurons

ATTAIN aims to rapidly translate genetic discoveries into gene-targeted therapies for ALS. By building a scalable pipeline using patient-derived motor neurons, the team will screen and optimize allele-specific antisense oligonucleotides, nominating lead candidates for safety testing and future first-in-human precision therapies.

Stefan Marciniak – AI-enabled diagnosis of Birt-Hogg-Dubé syndrome

This project applies federated learning and artificial intelligence to improve CT-based diagnosis of Birt-Hogg-Dubé syndrome using multi-institutional data without sharing patient information. By combining imaging, radiomics, and molecular data, the approach aims to improve diagnostic accuracy in non-specialist settings and establish a scalable, privacy-preserving framework for rare disease diagnostics.

Feyisayo Eweje – ENTER: Elastin-based nanoparticles for therapeutic delivery

This project is developing a non-viral protein nanoparticle system for targeted in vivo delivery of gene editors to hematopoietic stem cells. By overcoming key limitations of ex vivo gene editing, this platform aims to enable scalable genetic medicines for inherited blood and immune disorders such as sickle cell disease and beta-thalassemia.

Ana Topf – Latin-SEQ

Latin-SEQ is a multi-centre consortium focused on rare neuromuscular diseases in Latin America. The project integrates diagnosis, gene discovery, and translational development while building sustainable, locally owned scientific infrastructure. By enabling federated analyses and cross-site learning, Latin-SEQ promotes equitable collaboration and long-term capacity building in the region.

Annelisa Cornel – MetaboCAR

MetaboCAR is developing next-generation CAR-T therapies that exploit shared metabolic vulnerabilities across childhood cancers. By targeting metabolic stress signals rather than tumor-specific antigens, this approach aims to unlock new, broadly applicable immunotherapies for pediatric oncology.

Kim Fabiano Marquart – Nerai Bioscience

Nerai Bioscience combines AI with high-throughput directed evolution to engineer customized CRISPR gene-editing tools capable of targeting disease mutations currently beyond reach. With applications in rare genetic liver and metabolic diseases such as citrullinemia type I and phenylketonuria, the project seeks to expand access to first-in-class genome medicines.

Contact

EQT Press Office

press@eqtpartners.com

About EQT

EQT is a purpose-driven global investment organization focused on active ownership strategies. With a Nordic heritage and a global mindset, EQT has a track record of more than three decades of developing companies across multiple geographies, sectors and strategies. EQT has investment strategies covering all phases of a business’ development, from start-up to maturity. EQT has €‌​​270​‌ billion in total assets under management (€141​‌ billion in fee-generating assets under management) as of 31 December 2025, within two business segments – Private Capital and Real Assets.

With its roots in the Wallenberg family’s entrepreneurial mindset and philosophy of long-term ownership, EQT is guided by a set of strong values and a distinct corporate culture. EQT manages and advises funds and vehicles that invest across the world with the mission to future-proof companies, generate attractive returns and make a positive impact with everything EQT does.

The EQT AB Group comprises EQT AB (publ) and its direct and indirect subsidiaries, which include general partners and fund managers of EQT funds as well as entities advising EQT funds. EQT has offices in more than 25 countries across Europe, Asia and the Americas and has more than 1,900 employees.

More info: www.eqtgroup.com
Follow EQT on LinkedIn, X, YouTube and Instagram

Categories: News

Tags:

Ondal Medical Systems to acquire Völker Video- und Datentechnik GmbH

Hünfeld, Germany – 3rd February 2026 – Ondal Medical Systems GmbH (“Ondal”), a portfolio company of IK Partners (“IK”), has signed an agreement to acquire Völker Video- und Datentechnik GmbH (“Völker”), a founder-led specialist in high-definition and ultra-high definition (4K) video solutions for medical applications with a focus on cameras for surgical lights.

The acquisition marks the third add-on in Ondal’s buy-and-build strategy during IK’s ownership and represents an important step in broadening its offering beyond medical suspension systems, while further strengthening its position as a technology partner to leading MedTech Original Equipment Manufacturers (“OEMs”) and hospital integrators. Video solutions for medical applications, particularly surgical light systems, represent a highly complementary segment, supported by the growing need to document surgical procedures as well as the increasing importance of live training, remote collaboration and minimally invasive procedures. Völker founder Thomas Völker will remain with the business of Ondal Group, demonstrating his strong commitment to the long-term development of the combined platform.

The combination will enable Ondal to accelerate the development and scaling of this new segment by leveraging (i) an increasing share of wallet with complementary customers, including major MedTech OEMs and (ii) Völker’s electronics expertise in low-latency image processing, including capabilities relevant for 3D image representation in applications such as surgery, diagnostic, microscopy or endoscopy.

Dr. Markus Schneider, CEO of Ondal Medical Systems, commented: “The acquisition of Völker is a significant milestone for Ondal as we expand into video solutions for medical applications, a segment with clear clinical relevance and attractive long-term demand drivers. Völker’s technology and electronics expertise are highly complementary to Ondal’s platform, including its customer relationships and we look forward to working together to accelerate innovation and scale the offering globally.”

Thomas Völker, CEO / Founder of Völker, added: “I am very pleased to have found a strong and highly synergetic long-term home for Völker. Together with the Ondal team, we will build on our shared technological strengths, further develop our medical video solutions and actively shape the next phase of growth for the combined group.”

About Ondal Medical Systems

Ondal is a globally leading original design manufacturer of medical suspension systems for operating rooms, intensive care units and diagnostic environments, serving a blue-chip customer base of MedTech OEMs and hospital integrators.

About Völker Video- und Datentechnik GmbH

Völker is a founder-led specialist in high-definition and ultra-high definition (4K) video solutions for multiple medical applications with focus on cameras for surgical lights, serving a blue-chip customer base of MedTech OEMs.

Categories: News

Tags:

WindRose Health Investors Makes Investment in Avalon Healthcare Solutions

Franciso Partners

New York, NY, January 12, 2026 – WindRose Health Investors, LLC (“WindRose”), the New York-based healthcare private equity firm, announced that it has completed an investment in Avalon Healthcare Solutions (“Avalon” or the “Company”), a platform that integrates laboratory science and data to power real-time, lab-driven insights on behalf of health plan clients. Francisco Partners, a leading global investment firm that specializes in partnering with technology businesses, has also made an additional investment in the company. Avalon helps to ensure the appropriate use of routine and genetic lab tests and manages a national network of independent test providers.

WindRose’s investment and deep experience scaling tech-enabled payer services solutions will enable Avalon to accelerate its growth trajectory, invest in novel product offerings and further develop its next-generation technology platform. Avalon is uniquely positioned to address the complex and evolving needs of payers with its proprietary technology that automatically reviews and enforces lab test claims against client-adopted, clinically-derived policies. Avalon’s management team, headed by CEO Bill Kerr, will continue to lead the Company in its next phase of growth.

“We are grateful for Francisco Partners’ continued support and are excited to partner with WindRose and begin this next chapter,” said Mr. Kerr. “Francisco Partners has enabled us to grow and scale Avalon to where it is today, and we believe WindRose is a perfect additional partner to support the Company’s growth strategy of delivering an end-to-end lab benefit management platform. With the help of WindRose’s investment and strategic involvement, Avalon will continue to drive meaningful efficiencies on behalf of its health plan clients while also focusing on investing in innovation and building out its suite of capabilities.”

“Avalon has built a leadership position as a preferred partner to health plans that seek operational efficiencies while managing increasingly complex lab benefits. Avalon’s purpose-built lab insights platform uniquely combines lab benefits management, clinical science, and analytics to deliver value to its clients. We are thrilled to partner with Bill and the team to scale the business and continue to support product innovation,” said David Pontius, Partner at WindRose.

“Avalon has evolved into a differentiated, mission-critical partner for health plans by combining deep clinical expertise with a highly scalable technology platform,” said Ezra Perlman, Co-President of Francisco Partners. “We are excited to continue supporting Bill and the Avalon team as they invest in new product capabilities and drive meaningful impact for payers navigating an increasingly complex diagnostics landscape.”

William Blair acted as financial advisor to Avalon. McDermott Will & Schulte LLP acted as legal advisor to WindRose, Kirkland and Ellis acted as legal advisor to Francisco Partners and Davis Polk & Wardwell LLP acted as legal advisor to Avalon.

About WindRose Health Investors

New York City-based WindRose makes equity investments in companies that operate within the services sectors of the healthcare industry. The firm focuses on companies with profitable business models and a demonstrated ability to deliver cost-effective solutions. With approximately $7 billion under management, WindRose invests in companies throughout the United States. For more information, please email us at info@windrose.com.

About Francisco Partners

Francisco Partners is a leading global investment firm that specializes in partnering with technology and technology-enabled businesses. Since its launch over 25 years ago, Francisco Partners has invested in over 500 technology companies, making it one of the most active and longstanding investors in the technology industry. With over $50 billion in capital raised to date, the firm invests in opportunities where its deep sectoral knowledge and operational expertise can help companies realize their full potential. For more information on Francisco Partners, please visit www.franciscopartners.com.

About Avalon Healthcare Solutions

Headquartered in Tampa, Florida, Avalon is a healthcare technology company focused on managing the appropriate use of thousands of routine and genetic diagnostic laboratory tests on behalf of health plan clients. Avalon’s library of evidence-based lab policies is actively managed by a team of scientists and encoded into its proprietary platform to help payers reduce avoidable costs and improve clinical outcomes. For more information, please visit www.avalonhcs.com.

Contact:
Lambert by LLYC
Caroline Luz
cluz@lambert.com
203-570-6462

Categories: News

Tags:

EQT Life Sciences backs Kinaset Therapeutics’ USD103 million Series B to advance inhaled therapeutic for treatment of respiratory diseases

No Comments
EQT Life Science

EQT Life Sciences x Kinaset Therapeutics

  • EQT Life Sciences invests in U.S.-based Kinaset Therapeutics – a clinical-stage biopharma company developing a novel and differentiated inhaled therapeutic to treat serious respiratory diseases
  • Proceeds from the oversubscribed USD 103 million Series B round to help advance frevecitinib – a single-capsule dry powder inhaler delivering therapeutic lung concentrations, with the potential to treat the broad asthma population
  • EQT Life Sciences’ Daniela Begolo to join Kinaset Therapeutics’ Board of Directors

EQT Life Sciences is pleased to announce that the LSP 7 Fund has invested in Kinaset Therapeutics (the “Company”), a clinical-stage biopharmaceutical company based in Boston, U.S. developing a novel and differentiated inhaled therapeutic to treat serious respiratory diseases.

The investment was made as part of Kinaset’s oversubscribed USD 103 million Series B financing, led by RA Capital Management and Forge Life Science Partners, with participation from new investors EQT Life Sciences, Vivo, Schroders, Willett Advisors, Pictet, and Sixty Degree Capital, as well as existing investors Atlas Venture, 5AM Ventures, and Gimv.

Asthma affects millions of patients worldwide, yet a significant proportion remains inadequately controlled on existing therapies. Today’s biologic treatments mainly help patients with certain types of inflammation, leaving many with severe asthma without effective options. This has created a clear unmet need for broadly effective, safe, and inhaled anti-inflammatory therapies that can address the full spectrum of asthma disease.

Kinaset Therapeutics’s Series B will be used to help advance frevecitinib, a novel inhaled dry powder in development for patients with asthma that remains inadequately controlled by standard of care inhaled maintenance therapies. Frevecitinib is an inhaled pan-JAK inhibitor – an immune-modulating medication – designed to deliver therapeutic concentrations directly to the lungs via a single-capsule dry powder inhaler, while minimizing systemic exposure.
Daniela Begolo, Managing Director at EQT Life Sciences, who will join Kinaset’s Board of Directors, said: “Kinaset is taking a highly differentiated approach to asthma by pairing validated JAK biology with an inhaled delivery designed to maximize lung exposure while minimizing systemic risk. Backed by a strong and experienced management team, Kinaset has the potential to address a broad asthma population, including patients not well served by current therapies, making frevecitinib a particularly compelling program to advance into later-stage development.”

Robert Clarke, CEO of Kinaset Therapeutics, said: “Since day one, our goal has been to establish a best-in-class therapeutic for the treatment of severe inflammatory respiratory diseases. Critically, and unlike the majority of existing therapeutics, frevecitinib can provide benefit to all patients with severe asthma including those with a non-eosinophilic phenotype who continue to suffer from an absence of safe and effective therapies. This financing marks a significant milestone for Kinaset to execute our vision of advancing frevecitinib through a Phase 2 dose-ranging clinical study in severe asthma and potentially beyond. The participation of leading life science investors underscores both the strength of our team and the critical unmet need we aim to address.”

Contact
EQT Press Office, press@eqtpartners.com

Downloads

About EQT Life Sciences
EQT Life Sciences was formed in 2022 following an integration of LSP, a leading European life sciences and healthcare venture capital firm, into the EQT platform. As LSP, the firm raised over EUR 3.0 billion (USD 3.5 billion) and supported the growth of more than 150 companies since it started to invest over 30 years ago. With a dedicated team of highly experienced investment professionals, coming from backgrounds in medicine, science, business, and finance, EQT Life Sciences aims to back the smartest inventors who have ideas that could truly make a difference for patients.

More information: www.eqtgroup.com/private-capital/eqt-life-sciences

About Kinaset Therapeutics, Inc.
Kinaset Therapeutics is focused on developing inhaled therapeutics to address significant unmet medical needs in respiratory diseases. With founding investors 5AM Ventures, Atlas Venture and Gimv, the Company is pursuing a patient-focused approach to build a leading respiratory therapeutics company.

See more information at the Company’s website 

Categories: News

Tags:

819 Capital Partners acquires significant minority stake in RiverD

819 Capital Partners

Deventer, 5 January 2026 – 819 Capital Partners has acquired a significant minority participation in RiverD International. The investment, through 819 Evergreen Fund, is aimed at supporting RiverD’s long-term growth and development.

RiverD is a Dutch high-tech company developing and manufacturing advanced instruments for non-invasive molecular analysis of human skin and tissue using Raman spectroscopy. Its skin analysis technology enables real-time, reagentless measurement of skin tissue composition. RiverD’s other R&D-focus area is Raman-guided surgery based on fiber-optic technology.

The company’s solutions are used globally in medical and dermatological research, and cosmetic and pharmaceutical R&D.

RiverD was founded by Gerwin Puppels, who is widely regarded as one of the world’s leading experts in Raman spectroscopy and a pioneer in its application to biomedical research. As founder and CEO, he has been the driving force behind RiverD’s scientific vision, technological leadership, and international reputation.

The transaction reflects 819 Capital’s confidence in RiverD’s technology, market position, and long-term potential. Through the investment from the 819 Evergreen Fund, RiverD gains access to growth capital and strategic support to accelerate product development, international expansion, and further market adoption.

Categories: News

Tags:

With WA Beveiliging attracts Karmijn Kapitaal as growth partner for further growth within care security and public safety

Karmijn Kapitaal

Zeist, 5 january 2026 – Investor Karmijn Kapitaal is taking a majority stake in security organization Met WA Beveiliging. The Zeist-based company specializes in safety within care environments and community settings. The collaboration, which has been established under the guidance of Marktlink, is aimed at further growth in a consolidating market. Met WA Beveiliging and Karmijn Kapitaal want to realize growth through both organic growth and acquisitions.

Since 2016, Met WA has been providing security solutions in, among others, mental health care (GGZ), hospitals, youth care, reception locations and distribution centers. Security guards and Care & Safety employees work daily at locations where rapid signaling, maintaining calm and careful action are essential. In close collaboration with care professionals and other chain partners, they combine safety with practical support on the work floor, such as accompanying clients, supporting care providers and carrying out daily work activities within care institutions.

Own academy

Through its own Met WA Academy, employees receive practice-oriented training in, among other things, de-escalation, dealing with special behavior, risk management, aggression regulation and emergency response (BHV). This broad base makes teams deployable at diverse locations, from closed departments to the emergency room. The organization consists of 21 staff members and several hundred security professionals.

In recent years, Met WA expanded its field of work, among other things through the acquisition of the Nederlandse Veiligheidsgroep (NVG) in 2023. With this, in addition to care security, public safety also became a permanent part of the service provision.

Investment with positive social impact

Karmijn Kapitaal supports the further professionalization and growth of Met WA. As an investor, Karmijn focuses on SME companies with a positive social impact, among others within the themes of care and safety. “We have carefully prepared this step and consciously searched for a partner who shares our vision,” says founder Michiel Broeksma. “Together with Marktlink, we actively explored the market. In Karmijn Kapitaal, we have found the right party to further develop Met WA. This acquisition enables us to accelerate building a professional, scalable organization that is ready for the future.”

Karmijn underlines the distinctive character of the organization. “The need for safety in care and public domains continues to increase. At the same time, this requires different solutions than traditional security,” according to Nicole Zomerhuis of Karmijn Kapitaal. “Met WA offers a professional and people-oriented model that is scalable and broadly applicable. We are pleased to support the organization in increasing its positive impact on care and other social environments.”

Buy-and-build as growth path

The collaboration with Karmijn forms the starting point of a buy-and-build strategy. Met WA aims for targeted acquisitions of security companies within care, hospitality or public safety. “This transaction is a logical step within the consolidation wave in this sector,” says Jeffrey Scholtens, partner at Marktlink. “We see an increasing demand for security services that match the complexity of care and public environments, whereby tightened legislation and regulations around self-employed (zzp) constructions strengthen this demand. Met WA is a mature and distinctive player who is excellently positioned to play a central role in this dynamic. We facilitate the connection with parties that match the profile and ambitions of the organization through our network. Within the group that arises from this, the companies strengthen each other to become a leading player within (care) security.”

 

Categories: News

Tags:

Platinum Equity Completes Acquisition of Owens & Minor Products & Healthcare Services Business

Platinum

Two medical staff in full protective gear handle surgical instruments in a clinical setting, wearing masks, gowns, and bright green gloves. | Platinum Equity

P&HS anticipated to benefit from Platinum’s carve-out experience, sector expertise and commitment to growing the business

 P&HS will retain Owens & Minor brand and operate as a standalone company in Platinum’s portfolio

LOS ANGELES (Dec. 31, 2025) – Platinum Equity announced today that the acquisition of the Owens & Minor Products & Healthcare Services business (“Owens & Minor P&HS”) has been completed.

The transaction includes the Owens & Minor brand and the acquired business will continue to operate as Owens & Minor P&HS as a privately held standalone company in Platinum Equity’s portfolio.

The seller, which retained a five percent interest in the business, recently announced its remaining business will be rebranded Accendra Health, Inc., effective December 31, 2025.

Headquartered in Richmond, VA, Owens & Minor P&HS is a vertically integrated medical supply distribution platform primarily serving the acute care market. It is a leading national distributor of medical and surgical supplies for hospitals, health systems, and other healthcare providers across the United States.

“With our sector expertise, carve-out experience, and operational resources, we can help the company become an even more agile and responsive partner to the healthcare industry it serves. ”

Jacob Kotzubei, Co-President, Platinum Equity

“For more than 140 years, Owens & Minor has been guided by a strong sense of purpose, and we are proud to support its next chapter as a standalone business,” said Jacob Kotzubei, Co-President of Platinum Equity. “With our sector expertise, carve-out experience, and operational resources, we can help the company become an even more agile and responsive partner to the healthcare industry it serves. We will work with the company to strengthen its foundation, expand its capabilities, and ensure it continues delivering essential products and services when and where customers need them most.”

Platinum Equity has invested in numerous healthcare and supply chain businesses and has 30 years of experience acquiring and operating global businesses that have been part of large corporate entities. In recent years the firm has acquired businesses from firms like Caterpillar, Emerson Electric, Ingersoll Rand and Kohler, among others.

Platinum Equity Managing Director Matthew Louie said that continuity is critical to the transition process.

“Owens & Minor P&HS has a proud legacy of putting customers first, and we are excited to help carry that forward,” said Louie. “Our goal is to ensure continuity while making thoughtful improvements that keep the company dynamic, responsive, and aligned with the evolving needs of its customers. We will work closely with the team to help strengthen fulfillment performance, drive operational excellence across manufacturing and distribution, and accelerate growth in proprietary products. At the same time, we will invest in supply chain enhancements to help improve efficiency and resiliency.”

Bank of America and Fifth Third served as financial advisors to Platinum Equity on the P&HS acquisition. Gibson, Dunn & Crutcher LLP served as legal advisor, Willkie Farr & Gallagher LLP served as debt financing counsel, and Latham & Watkins LLP served as special regulatory counsel to Platinum Equity on the transaction.

Citi and Wells Fargo acted as financial advisors to Owens & Minor. Kirkland & Ellis served as Owens & Minor’s legal advisor.

About Platinum Equity

Founded in 1995 by Tom Gores, Platinum Equity is a global investment firm with approximately $50 billion of assets under management and a portfolio of approximately 60 operating companies that serve customers around the world. Platinum Equity specializes in mergers, acquisitions and operations – a trademarked strategy it calls M&A&O® – acquiring and operating companies in a broad range of business markets, including manufacturing, distribution, transportation and logistics, equipment rental, metals services, media and entertainment, technology, telecommunications and other industries. Over the past 30 years Platinum Equity has completed more than 500 acquisitions

Published: Friday, January 2, 2026 | Updated: Friday, January 2, 2026

Categories: News

Tags: